Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

AIM: Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this stud...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:CNS Neurosci Ther
Main Authors: Mansilla, María José, Navarro‐Barriuso, Juan, Presas‐Rodríguez, Silvia, Teniente‐Serra, Aina, Quirant‐Sánchez, Bibiana, Ramo‐Tello, Cristina, Martínez‐Cáceres, Eva María
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6698982/
https://ncbi.nlm.nih.gov/pubmed/31066225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13142
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker